MaxCyte, Inc. (MXCT)

MaxCyte reported a Q1 2025 loss per share of -$0.10 and partnered with Ori Biotech to enhance cell therapy manufacturing. Shareholders approved a common stock cancellation date. The company reported a Q2 2025 loss per share of -$0.12, missing estimates, and revenue of $8.51 million, which was below expectations, subsequently lowering its 2025 earnings guidance. CEO Maher Masoud and Director William W. Brooke acquired shares, while analyst ratings included downgrades. Strategic Platform License Agreements were announced with Anocca AB and Moonlight Bio. An operational restructuring was announced to reduce costs and accelerate profitability, and a Platform License Agreement was signed with Adicet Bio. MaxCyte's stock price declined by 55.47% from October 22, 2024, to October 21, 2025, gained 0.617% on October 24, 2025, but had fallen 10.93% since October 15, 2025. Q3 2025 financial results are expected on November 5, 2025.

MaxCyte's annual report acknowledges that seasonal demands could impact the company's performance. The company aims to maintain sufficient inventory levels and relies on its commercial team and distributors for forecasts of anticipated product orders. Specific patterns or detailed information regarding the nature of these seasonal demands for MaxCyte's products and services are not publicly detailed in the provided information.

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance cell therapeutics. Its core business uses Flow Electroporation® technology, central to its ExPERT™ platform, which supports the cell therapy market by modifying cell types. The ExPERT platform includes instruments like ATx, STx, GTx, and VLx, with processing assemblies and software. MaxCyte offers off-target risk assessment solutions for gene editing through its SeQure™ services. The company generates revenue through instrument sales, consumables, and licensing agreements.

MaxCyte operates globally, partnering with academic institutions, translational centers, and biopharmaceutical companies. The company's headquarters are in Gaithersburg, Maryland, within Maryland's I-270 Biotech Corridor. Its ExPERT platform is available globally, supported by international distributors.

MaxCyte has maintained a positive brand reputation, celebrating its 25th anniversary in November 2024. Its role in the development of CASGEVY®, the first FDA-approved non-viral cell therapy, boosted its reputation. New SPL agreements with Moonlight Bio, Adicet Bio, and Anocca AB, and the partnership with Ori Biotech, further solidify its industry position.

MaxCyte, Inc. has a significant institutional ownership base, with 259 institutional owners and shareholders holding a total of 81,442,609 shares. Major institutional owners include BlackRock, Inc., Cadian Capital Management, Lp, Morgan Stanley, Mirabella Financial Services Llp, Vanguard Group Inc, Vitruvian Partners LLP, Mudita Advisors LLP, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, IWM - iShares Russell 2000 ETF, and Geode Capital Management, Llc. Institutional ownership accounts for 69.24% of the company, while individuals hold 2.26%, and corporate insiders own 3.30% of the stock.